Dilley Robert L, Greenberg Roger A
Departments of Cancer Biology and Pathology, Abramson Family Cancer Research Institute, Basser Research Center for BRCA, Perelman School of Medicine, University of Pennsylvania, 421 Curie Boulevard, Philadelphia, PA 19104, USA.
Trends Cancer. 2015 Oct 1;1(2):145-156. doi: 10.1016/j.trecan.2015.07.007.
Activation of a telomere maintenance mechanism (TMM) is permissive for replicative immortality and a hallmark of human cancer. While most cancers rely on reactivation of telomerase, a significant fraction utilizes the recombination dependent alternative lengthening of telomeres (ALT) pathway. ALT is enriched in tumors of mesenchymal origin, including those arising from bone, soft tissue, and the nervous system, and usually portends a poor prognosis. Recent insights into the mechanisms of ALT are uncovering novel avenues to exploit vulnerabilities and may facilitate clinical development of ALT detection assays and personalized treatment decisions based on TMM status. Treatments targeting ALT may hold promise for a broadly applicable therapeutic modality specific to mesenchymal lineage tumors, something that has thus far remained elusive.
端粒维持机制(TMM)的激活是细胞复制永生的必要条件,也是人类癌症的一个标志。虽然大多数癌症依赖端粒酶的重新激活,但相当一部分癌症利用依赖重组的端粒替代延长(ALT)途径。ALT在间充质起源的肿瘤中富集,包括骨、软组织和神经系统来源的肿瘤,通常预示着预后不良。最近对ALT机制的深入了解正在揭示利用其弱点的新途径,并可能促进基于TMM状态的ALT检测方法的临床开发和个性化治疗决策。针对ALT的治疗可能为间充质谱系肿瘤提供一种广泛适用的治疗方式,而这一点迄今为止仍难以实现。